Skip to main content
Clinical Trials/CTRI/2018/02/011933
CTRI/2018/02/011933
Not yet recruiting
未知

Assessment of Clinical Profile of Patients of Chronic Heart Failure with Iron Deficiency Treated with Intravenous Ferric Carboxymaltose 1000 mg:- PRIDE-HF India Study - PRIDE-HF India

Emcure Pharmaceuticals Ltd0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Emcure Pharmaceuticals Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Indian adult ( \>18 years of age) patients of either gender who are capable of complying with study protocol
  • requirements
  • 2\. Stable ambulatory patients with chronic heart failure of New York Heart Association (NYHA) class I â?? IV and iron
  • deficiency. Iron deficiency is diagnosed when the serum ferritin level is less than 100 μg/L or is between 100 and 299
  • μg/L when the transferrin saturation (TSAT) is less than 20%
  • 3\. Patients treated with injection ferric carboxymaltose 1000 mg as per approved prescribing information.
  • 4\. Patients whose ejection fraction, serum ferritin and Hb levels are available at the start of FCM therapy.

Exclusion Criteria

  • 1\. Patients with incomplete health record as per the requirement of protocol
  • 2\. Patients not willing to sign Informed Consent Form and provide medical data
  • 3\. Pregnant and lactating women

Outcomes

Primary Outcomes

Not specified

Similar Trials